<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Xtl Biopharmaceuticals Ltd — News on 6ix</title>
<link>https://6ix.com/company/xtl-biopharmaceuticals-ltd</link>
<description>Latest news and press releases for Xtl Biopharmaceuticals Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 20 Mar 2026 20:10:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/xtl-biopharmaceuticals-ltd" rel="self" type="application/rss+xml" />
<item>
<title>XTL Biopharmaceuticals Announces ADS Ratio Change</title>
<link>https://6ix.com/company/xtl-biopharmaceuticals-ltd/news/xtl-biopharmaceuticals-announces-ads-ratio-change</link>
<guid isPermaLink="true">https://6ix.com/company/xtl-biopharmaceuticals-ltd/news/xtl-biopharmaceuticals-announces-ads-ratio-change</guid>
<pubDate>Fri, 20 Mar 2026 20:10:00 GMT</pubDate>
<description>RAMAT GAN, ISRAEL, March 20, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares, par value NIS0.1 per share (the "ADS Ratio"), from the current ADS Ratio of one (1) ADS to one hundred (100) ordinary shares, to a new ADS Ratio of one (1) ADS to four hundred (400) ordinary shares (the "ADS Ratio Change"). The Company anticipate</description>
</item>
<item>
<title>XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing</title>
<link>https://6ix.com/company/xtl-biopharmaceuticals-ltd/news/xtl-announces-receipt-of-staff-delist-determination-from-nasdaq-and-plans-to-request-hearing</link>
<guid isPermaLink="true">https://6ix.com/company/xtl-biopharmaceuticals-ltd/news/xtl-announces-receipt-of-staff-delist-determination-from-nasdaq-and-plans-to-request-hearing</guid>
<pubDate>Fri, 27 Feb 2026 21:30:00 GMT</pubDate>
<description>RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) from The Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), dated February 25, 2026, notifying the Company of the Staff’s belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a “public shell”, and that continu</description>
</item>
<item>
<title>XTL Update on Recent Developments</title>
<link>https://6ix.com/company/xtl-biopharmaceuticals-ltd/news/xtl-recent-developments-210500535</link>
<guid isPermaLink="true">https://6ix.com/company/xtl-biopharmaceuticals-ltd/news/xtl-recent-developments-210500535</guid>
<pubDate>Thu, 29 Jan 2026 21:05:00 GMT</pubDate>
<description>RAMAT GAN, ISRAEL, Jan. 29, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced that it is working diligently to close the acquisition of 85% of the shares of NeuroNOS Ltd. from Beyond Air Inc, following the execution of the Binding Letter of Intent on January 13 , 2026 (as disclosed in the Company’s Report of Foreign Private Issuer on Form 6-K filed on January 13, 2026), and has already scheduled a shareholders meeting for Februa</description>
</item>
<item>
<title>XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency</title>
<link>https://6ix.com/company/xtl-biopharmaceuticals-ltd/news/xtl-announces-receipt-nasdaq-notification-211000710</link>
<guid isPermaLink="true">https://6ix.com/company/xtl-biopharmaceuticals-ltd/news/xtl-announces-receipt-nasdaq-notification-211000710</guid>
<pubDate>Fri, 23 Jan 2026 21:10:00 GMT</pubDate>
<description>RAMAT GAN, ISRAEL, Jan. 23, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated January 20, 2026, notifying the Company that the Company currently does not meet the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(b)(1), to maintain a minimum of $2,500,000 in stockhold</description>
</item>
<item>
<title>XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership</title>
<link>https://6ix.com/company/xtl-biopharmaceuticals-ltd/news/xtl-biopharmaceuticals-acquires-85-neuronos-142800878</link>
<guid isPermaLink="true">https://6ix.com/company/xtl-biopharmaceuticals-ltd/news/xtl-biopharmaceuticals-acquires-85-neuronos-142800878</guid>
<pubDate>Tue, 13 Jan 2026 14:28:00 GMT</pubDate>
<description>Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying therapies exist FDA Orphan Drug designations secured for autism-related Phelan-McDermid Syndrome (PMS) and Glioblastoma Platform targets the core biology of autism, not just symptomatic relief Beyond Air (NASDAQ: XAIR), majority owner of NeuroNOS, to hold 19.99% of XTL's post-transaction</description>
</item>
<item>
<title>XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership</title>
<link>https://6ix.com/company/xtl-biopharmaceuticals-ltd/news/xtl-biopharmaceuticals-acquires-85-beyond-123000855</link>
<guid isPermaLink="true">https://6ix.com/company/xtl-biopharmaceuticals-ltd/news/xtl-biopharmaceuticals-acquires-85-beyond-123000855</guid>
<pubDate>Tue, 13 Jan 2026 12:30:00 GMT</pubDate>
<description>Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying therapies exist FDA Orphan Drug designations secured for autism-related Phelan-McDermid Syndrome (PMS) and Glioblastoma Platform targets the core biology of autism, not just symptomatic relief Beyond Air (NASDAQ: XAIR), majority owner of NeuroNOS, to hold 19.99% of XTL's post-transaction</description>
</item>
<item>
<title>XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency</title>
<link>https://6ix.com/company/xtl-biopharmaceuticals-ltd/news/xtl-announces-receipt-nasdaq-notification-210000570</link>
<guid isPermaLink="true">https://6ix.com/company/xtl-biopharmaceuticals-ltd/news/xtl-announces-receipt-nasdaq-notification-210000570</guid>
<pubDate>Wed, 24 Dec 2025 21:00:00 GMT</pubDate>
<description>RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated December 22, 2025, notifying the Company that based on XTL’s closing bid price for the last 30 consecutive business days, the Company currently does not meet the continued listing requirement of Nasdaq, under Nasd</description>
</item>
<item>
<title>XTL Names Mr. Noam Band as its New Chief Executive Officer</title>
<link>https://6ix.com/company/xtl-biopharmaceuticals-ltd/news/xtl-names-mr-noam-band-131500208</link>
<guid isPermaLink="true">https://6ix.com/company/xtl-biopharmaceuticals-ltd/news/xtl-names-mr-noam-band-131500208</guid>
<pubDate>Mon, 07 Apr 2025 13:15:00 GMT</pubDate>
<description>Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”) announced today the appointment of Noam Band as the Company’s new Chief Executive Officer. Shlomo Shalev will continue as the Chairman of the Board of Directors. Previously, Mr. Band has served as the Chairman and Chief Executive Officer of Gix Internet Ltd. (formerly Algomizer Ltd.) (TASE:GIX), a publicl</description>
</item>
</channel>
</rss>